Melanoma of unknown primary site : Presentation, treatment, and prognosis—a single institution study
✍ Scribed by Kevin K. Anbari; Lynn M. Schuchter; Louis P. Bucky; Rosemarie Mick; Marie Synnestvedt; DuPont Guerry IV; Ralph Hamilton; Allan C. Halpern
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 123 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
RESULTS.
Sixty-five percent of the patients presented with lymph node metastasis for the University of Pennsylvania only, 28% presented with visceral lesions, and 8% presented with subcutaneous
Pigmented Lesion Study Group
nodules. The prevalence of dysplastic nevi was 22.5%. The overall 4-year survival rate for the 40 MUP patients was 55% { 9%. The 4-year survival (57% { 12%) of
📜 SIMILAR VOLUMES
Background. Patients with advanced, inoperable head and neck cancers have cure rates of approximately 10-15%. In these patients, concomitant chemoradiotherapy seems to improve local control and survival. 5-Fluorouracil(5-FU) administered by continuous infusion and cisplatin plus concomitant conventi
## BACKGROUND. When skeletal metastasis is the presenting problem and the primary site is occult, there is a need to identify the primary site as soon as possible. However, the search for the primary tumor is often time-consuming and difficult. The purpose of this study was to analyze the effica